Scintimun is an internationally approved product [2] and has previously been manufactured and distributed by Curium Pharma through an out-license from Telix via the acquisition of TheraPharm in ...

PARIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with ...

Curium, a world leader in nuclear medicine, announced that Pylclari is now available for patients with prostate cancer in Estonia, Finland, Latvia, and Sweden. Pylclari (INN: Piflufolastat (18F) also ...

PARIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has expanded its existing partnership with Institute of Isotopes Co. Ltd. (Izotop ...

The agreement also includes a strategic contract manufacturing agreement appointing Curium as the manufacturer of the product for Telix. Kevin Richardson, Chief Executive Officer, Telix Precision ...

Today will see any patchy low cloud and fog lift early leaving a dry day with plenty of winter sunshine. It will continue chilly. Tonight Tonight will start clear but bands of cloud will move in ...

Today will see any fog clear early on, but cloudy skies will remain again, with only a few rare bright breaks. Another dry, mild and settled day. Tonight Tonight will remain largely cloudy ...

PARIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has expanded its existing partnership with Institute of Isotopes Co. Ltd. (Izotop) to make ...

PYLCLARI ® is being produced by Curium at its facilities in Helsinki, Finland – ensuring distribution to Estonia, Finland, Latvia, and Sweden. For more information about PYLCLARI ®: www.pylclari.com ...

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement ...